Supporting the

Neuroendocrine Cancer Community

National COVID Cancer survey

Sep 20, 2021

Further to our News Item last week (15th Sept) – here is an update and the link required to get involved: National COVID Cancer survey

To improve the understanding of the protection provided by antibodies generated following COVID-19 infection and vaccination in individuals with cancer.

The survey looks to include 10,000 cancer patients – who have received a cancer treatment anytime over the last 12 months – this includes those diagnosed with Neuroendocrine Cancer and ALL Neuroendocrine Cancer treatments e.g. somatostatin analogues, PRRT, as well as chemotherapy and / or targeted molecular therapies such as Everolimus and Sunitinib. The survey investigators are keen to include as many less common and rare cancers, as common cancers – and that includes those with Neuroendocrine Cancer (NETs and NECs).

This survey is being conducted to look at whether patients with active cancer, either diagnosed in the last year or who are having treatment, have antibodies to COVID-19. Individuals with cancer might have developed antibodies after a previous infection or COVID-19 vaccination. Some patients with cancer have a weakened immune system because of the cancer or cancer treatment and it is not known how this effects your body’s ability to produce antibodies to COVID-19.

To find out more about the survey and how you can get involved – click here

**Please note that when completing the survey, a message may appear stating that you need to be in employment to complete the survey – please just bypass this and continue completing the survey**